Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial.

Ignatenko S, Skrumsager BK, Mouritzen U.

Int J Clin Pharmacol Ther. 2016 Apr;54(4):243-52. doi: 10.5414/CP202474.

PMID:
26833462
2.

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, Kristjansen PE, McArthur G.

Clin Cancer Res. 2009 Mar 15;15(6):2123-9. doi: 10.1158/1078-0432.CCR-08-2663. Epub 2009 Mar 10.

3.

IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma.

Frederiksen KS, Lundsgaard D, Freeman JA, Hughes SD, Holm TL, Skrumsager BK, Petri A, Hansen LT, McArthur GA, Davis ID, Skak K.

Cancer Immunol Immunother. 2008 Oct;57(10):1439-49. doi: 10.1007/s00262-008-0479-4. Epub 2008 Feb 20.

4.

An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.

Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, Moller NP, Skak K, Lundsgaard D, Frederiksen KS, Thygesen P, McArthur GA.

Clin Cancer Res. 2007 Jun 15;13(12):3630-6.

5.

Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.

Skrumsager BK, Nielsen KK, Müller M, Pabst G, Drake PG, Edsberg B.

J Clin Pharmacol. 2003 Nov;43(11):1244-56.

PMID:
14551179
6.

Safety and pharmacokinetics of ReN1869: a first human dose study in healthy subjects after single-dose administration.

Skrumsager BK, Ingwersen SH, Gerrits M.

J Clin Pharmacol. 2003 Jan;43(1):66-73.

PMID:
12520630
7.
8.

Pharmacokinetics of levormeloxifene in young versus elderly postmenopausal women.

Kiehr B, Skrumsager BK, Müller M, Pedersen PC.

Clin Ther. 2001 Jan;23(1):62-71.

PMID:
11219480
9.

NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia.

Karle J, Clemmesen L, Hansen L, Andersen M, Andersen J, Fensbo C, Sloth-Nielsen M, Skrumsager BK, Lublin H, Gerlach J.

Psychopharmacology (Berl). 1995 Oct;121(3):328-9. No abstract available.

PMID:
8584614
10.

Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects.

Skrumsager BK, Christensen JV, Snel S, Seiberling M.

Psychopharmacology (Berl). 1995 Oct;121(3):294-9.

PMID:
8584609
11.

A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects.

Søgaard U, Michalow J, Butler B, Lund Laursen A, Ingersen SH, Skrumsager BK, Rafaelsen OJ.

Int Clin Psychopharmacol. 1990 Oct;5(4):237-51.

PMID:
2150527
13.
14.

Femoxetine and amitriptyline in general practice: a randomized double-blind group comparison.

Skrumsager BK, Jeppesen K.

Pharmacopsychiatry. 1986 Sep;19(5):368-77.

PMID:
3774871
15.

[Treatment of obesity in general practice with femoxetine. A controlled clinical trial of the effects of femoxetine and placebo].

Kristensen JS, Christiansen P, Skrumsager BK.

Ugeskr Laeger. 1982 Mar 29;144(13):939-42. Danish. No abstract available.

PMID:
7048680
16.

Brain levels of l-alpha--acetylmethadol (LAAM) and metabolites in the rat: correlation with pharmacological effects.

Skrumsager BK, Henderson GL.

Proc West Pharmacol Soc. 1977;20:473-6. No abstract available.

PMID:
896857

Supplemental Content

Loading ...
Support Center